Mabpharm (HKSE:02181) Price-to-Tangible-Book : 6.39 (As of May. 31, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Price-to-Tangible-Book?

As of today (2024-05-31), Mabpharm's share price is HK$0.345. Mabpharm's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$0.05. Hence, Mabpharm's Price to Tangible Book Ratio of today is 6.39.

The historical rank and industry rank for Mabpharm's Price-to-Tangible-Book or its related term are showing as below:

HKSE:02181' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.99 Med: 4.15 Max: 8.52
Current: 6.9

During the past 7 years, Mabpharm's highest Price to Tangible Book Ratio was 8.52. The lowest was 3.99. And the median was 4.15.

HKSE:02181's Price-to-Tangible-Book is ranked worse than
80.8% of 1219 companies
in the Biotechnology industry
Industry Median: 2.77 vs HKSE:02181: 6.90

A closely related ratio is called PB Ratio. As of today, Mabpharm's share price is HK$0.345. Mabpharm's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$0.05. Hence, Mabpharm's P/B Ratio of today is 6.39.

Mabpharm Price-to-Tangible-Book Historical Data

The historical data trend for Mabpharm's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Price-to-Tangible-Book Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.05

4.15

5.59

3.99

8.52

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial								5.59	4.36	3.99	6.11	8.52

Competitive Comparison of Mabpharm's Price-to-Tangible-Book

For the Biotechnology subindustry, Mabpharm's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Mabpharm's Price-to-Tangible-Book falls into.

Mabpharm Price-to-Tangible-Book Calculation

Mabpharm's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.345	/	0.054
	=	6.39

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Mabpharm Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Mabpharm's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines